Bowman-Birk proteinase inhibitor (BBI) modulates radiosensitivity and radiation-induced differentiation of human fibroblasts in culture.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 7597212.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The radiosensitivity and differentiation pattern of cultured normal human fibroblasts was analysed as a function of treatment of the cells with the Bowman-Birk proteinase inhibitor (BBI). Upon irradiation with doses from 0 to 8 Gy normal human fibroblasts are induced to a premature terminal differentiation within 14-21 days of postirradiation incubation. Treatment of the cells with 10 microM BBI for 2 h prior to the irradiation procedure resulted in a significant shift of the radiation survival curve, increased SF2 values 0.63 vs. 0.84 and the cell type composition of the test fibroblast cultures. Upon pretreatment with BBI the radiation-induced premature terminal differentiation of progenitor fibroblasts to postmitotic fibrocytes could significantly be inhibited. Based on this data, it can be postulated that BBI may serve as a radioprotector of normal fibroblasts which are involved in radiation-induced tissue injuries like radiation fibrosis.
Medical subject headings
- Fibroblasts
- Radiation Tolerance
- Radiation-Protective Agents
- Trypsin Inhibitor, Bowman-Birk Soybean